- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02941081
A Novel Nano-iron Supplement to Safely Combat Iron Deficiency and Anaemia in Young Children: a Doubleblind Randomised Controlled Trial (IHAT-Gut)
A Novel Nano-iron Supplement (IHAT) to Safely Combat Iron Deficiency and Anaemia (IDA) in Young Children: a Doubleblind Randomised Controlled Trial
This study aims to determine whether IHAT is non-inferior to ferrous sulphate at correcting iron deficiency and anaemia, and if IHAT does not increase diarrhoea risk in young children living in rural and resource-poor areas of the Gambia.
The study hypothesis is that IHAT will eliminate iron deficiency and improve haemoglobin levels in young children without increasing infectious diarrhoea or promoting inflammation in the gut.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objectives of this trial are: (i) show non-inferiority of IHAT compared to ferrous sulphate for efficacy (in terms of Hb and iron deficiency correction); (ii) show superiority of IHAT compared to ferrous sulphate in terms of moderate-severe diarrhoea (incidence and prevalence); (iii) show non-inferiority of IHAT compared to placebo in terms of prevalence of moderate-severe diarrhoea.
Secondary objectives are: (i) show that IHAT supplementation does not increase enteric pathogen burden; (ii) show that IHAT supplementation is non-detrimental to the gut microbiome; (iii) show that IHAT supplementation does not cause intestinal inflammation; (iv) describe the impact of IHAT supplementation on hospitalisation and morbidity; (v) determine the effect of IHAT supplementation on systemic inflammation; (vi) determine the effect of IHAT supplementation on systemic markers of iron handling.
To investigate the primary and secondary objectives the investigators will conduct a 3-arm, parallel, randomised, double-blind, placebo-controlled, phase 2, clinical trial.
Participants will be iron deficient anaemic young children living in rural communities in the North Bank of the Upper River Division in The Gambia.
The communities and health centres within the study catchment area (Wuli and Sandu districts) will be sensitised to the study. Young children will be identified using the immunisation records at the health centres. At screening, once mothers/guardians of the child have signed the informed consent form, the child will be physically examined by a study nurse and, if the child is considered as generally healthy, their height and weight will be measured and a finger prick blood sample will be collected for Hb and RDT testing. If z-scores are >-3, 7 ≤Hb< 11 g/dL and the RDT is negative, a small venous blood sample will be collected to confirm the Hb levels and determine serum ferritin. A total of 705 eligible children will be randomised into the 3 study arms (n=235 per arm).
In each study arm, the children will be supplemented daily for 12 weeks (84 days) with either placebo, ferrous sulphate or IHAT. Blood and stool samples will be collected at baseline (Day 1) and at day 15 and day 85 during the intervention period. Following the 12 weeks of intervention there will be an additional active follow-up period of 4 weeks without intervention.
Highly trained and experienced field workers will be visiting all children every day during the 12 weeks supplementation period in order to administer the iron supplements or placebo and on these occasions they will check on the children's general health and actively look for signs of malaria and co-infections. If a child shows signs of these infections, the field worker will refer to the study nurse who will perform adequate tests and the child will be offered the appropriate treatment/referral to the next health center. Three times per week, morbidity data (including questions regarding fever, diarrhoea, vomiting, cough, any other illness, appetite and any mediation taken and assessment of body temperature) will be captured. Every week children will be screened using a finger prick blood sample to determine their malaria and Hb status and children found with a positive RDT during the study will be further tested with a blood film and treated according to national guidelines. These visits will continue 4 weeks post intervention to follow-up on AE/SAEs. Any child where Hb falls below 7 g/dL during the follow-up study period will stop the study and will be referred to the next health centre for managemen
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Upper River Region
-
Basse, Upper River Region, Gambia
- MRC Unit The Gambia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6-35 mo.
- Free of malaria (RDT negative)
- HAZ, WAZ, WHZ >-3 SD
- IDA defined as 7≤ Hb <11 g/dl AND ferritin<30 μg/L
- Resident in the study area (and planning to remain in the study area for the duration of the trial)
- Ability and willingness to comply with the study protocol (daily intake of supplement and daily study visits with weekly finger prick)
- Informed consent given by parent or guardian
Exclusion Criteria:
- Congenital disorders
- Chronic disease
- Currently participating in another study
- Currently taking iron supplements/multiple micronutrient supplements
- Currently experiencing moderate-severe diarrhoea, defined as those diarrhoea episodes where (i) the child passes more than 5 loose or watery stools per day, (ii) there is blood in the stool (dysentery), or (iii) the child shows signs of clinical dehydration (assessed by the study nurse based on physical signs such as little or no urination, sunken eyes, and skin that lacks its normal elasticity), will usually require treatment (including ORS)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IHAT
IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e.
20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
|
1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e.
20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
|
Active Comparator: ferrous sulphate
Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
|
1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
|
Placebo Comparator: placebo
Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
|
1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of children with iron deficiency
Time Frame: at 12 weeks
|
Proportion of children at 12 weeks with iron deficiency (Cobas analyser).
The choice of the marker to use to define iron deficiency will be made at the time of locking the data analysis plan and we will use the most up to date WHO recommendation at the time.
But most likely it will be: ferritin <12 mcg/liter, or <30 mcg/liter in the presence of inflammation (CRP>5), and (soluble transferrin receptor - sTfR)/log10 ferritin index >2.
|
at 12 weeks
|
Proportion of children with anaemia
Time Frame: at 12 weeks
|
Proportion of children at 12 weeks with anaemia (Medonic analyser).
Anaemia is defined as haemoglobin < 11 g/dl.
|
at 12 weeks
|
incidence density' of moderate-severe diarrhea episodes
Time Frame: over 12 weeks
|
Incidence density of moderate-severe diarrhoea episodes over the 12 weeks (questionnaire/assessment by study nurse).
Incidence density is defined as the number of new episodes of moderate-severe diarrhoea per child over the 12 weeks intervention
|
over 12 weeks
|
period prevalence of moderate-severe diarrhoea
Time Frame: over 12 weeks
|
Period prevalence of moderate-severe diarrhea over the 12 weeks (questionnaire/assessment by study nurse).
Period prevalence is defined as the proportion of children with at least one episode of moderate-severe diarrhea over the 12 weeks intervention
|
over 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alpha diversity and beta diversity of the faecal microbiome
Time Frame: at baseline, 4 weeks and 12 weeks
|
Alpha diversity and beta diversity of the faecal microbiome at baseline, 4 weeks and 12 weeks data from MiSeq sequencing of faecal 16S rRNA)
|
at baseline, 4 weeks and 12 weeks
|
hospitalisation events
Time Frame: over 12 weeks period
|
Number of new hospitalization events per child over the 12 weeks (questionnaire
|
over 12 weeks period
|
Ratio of enterobacteria/(bifidobacteria+lactobacilli) abundances
Time Frame: at baseline, 4 weeks and 12 weeks
|
Ratio of enterobacteria/(bifidobacteria+lactobacilli) abundances in the faecal microbiome at baseline, 4 weeks and 12 weeks (data from MiSeq sequencing of faecal 16S rRNA)
|
at baseline, 4 weeks and 12 weeks
|
Proportion of children with episodes of respiratory tract infections and malaria
Time Frame: over 12 weeks
|
Proportion of children with episodes of respiratory tract infections and malaria over the 12 weeks (questionnaire)
|
over 12 weeks
|
Proportion of children with enteric pathogens
Time Frame: at baseline, 4 weeks and 12 weeks
|
Proportion of children with enteric pathogens at baseline, 4 weeks and 12 weeks (targeted qPCR)
|
at baseline, 4 weeks and 12 weeks
|
Gut inflammation
Time Frame: baseline day 1, day 15 and day 85
|
Gut inflammation measured with faecal calprotectin (ELISA)
|
baseline day 1, day 15 and day 85
|
Longitudinal prevalence of moderate-severe diarrhoea
Time Frame: over 12 weeks
|
Longitudinal prevalence of moderate-severe diarrhoea (questionnaire/assessment by study nurse).
Longitudinal prevalence is defined as the number of days a child has moderate-severe diarrhea over the 12 weeks intervention
|
over 12 weeks
|
Incidence density of 'bloody' diarrhea per month
Time Frame: per month
|
Incidence density of 'bloody' diarrhea per month (questionnaire/assessment by study nurse).
Defined as the number of diarrhea episodes with blood in the stool, as a sign of severe intestinal infection, per child-month of observation
|
per month
|
Serum C-reactive protein and Alpha-1-acid glycoprotein
Time Frame: baseline day 1, day 15 and day 85
|
Serum C-reactive protein and Alpha-1-acid glycoprotein (Cobas analyser).
Markers of systemic inflammation
|
baseline day 1, day 15 and day 85
|
Serum hepcidin
Time Frame: baseline 1day 1, day 15 and day 85
|
Serum hepcidin (ELISA).
Marker of systemic iron handling
|
baseline 1day 1, day 15 and day 85
|
Serum non-transferrin bound iron
Time Frame: baseline day 1, day 15 and day 85
|
Serum non-transferrin bound iron (flurescence chemical assay).
Marker of systemic iron handling.
|
baseline day 1, day 15 and day 85
|
Transferrin saturation
Time Frame: baseline5day 1, day 14 and day 85
|
Transferrin saturation (Cobas analyser).
Marker of systemic iron handling
|
baseline5day 1, day 14 and day 85
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Dora Pereira, PhD, Cambridge University, UK
Publications and helpful links
General Publications
- de Goffau MC, Jallow AT, Sanyang C, Prentice AM, Meagher N, Price DJ, Revill PA, Parkhill J, Pereira DIA, Wagner J. Gut microbiomes from Gambian infants reveal the development of a non-industrialized Prevotella-based trophic network. Nat Microbiol. 2022 Jan;7(1):132-144. doi: 10.1038/s41564-021-01023-6. Epub 2021 Dec 31.
- Pereira DIA, Mohammed NI, Ofordile O, Camara F, Baldeh B, Mendy T, Sanyang C, Jallow AT, Hossain I, Wason J, Prentice AM. A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol. Gates Open Res. 2018 Oct 11;2:48. doi: 10.12688/gatesopenres.12866.2. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCC 1489
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency, Anaemia in Children
-
Shield TherapeuticsMedpace, Inc.CompletedIron Deficiency, Anaemia in Children | Iron-DeficiencyUnited Kingdom
-
Pharmacosmos A/SRecruitingIron Deficiency, Anaemia in ChildrenUnited States
-
Nadirah Rasyid RidhaHasanuddin UniversityCompletedIron Deficiency, Anaemia in ChildrenIndonesia
-
Mahidol UniversityCompletedEffect of a Dietary Iron Program on Iron Status and IQ in Children in Phatthalung Province, ThailandIron Deficiency, Anaemia in ChildrenThailand
-
Assiut UniversityUnknownLiver Cirrhosis | Iron Deficiency, Anaemia in Children
-
London School of Hygiene and Tropical MedicineUniversity of OxfordRecruitingIron Deficiency, Anaemia in ChildrenGambia
-
London School of Hygiene and Tropical MedicineCompletedIron-deficiency | Anaemia in Early InfancyGambia
-
Saskatchewan Health Authority - Regina AreaSaskatchewan Centre for Patient-Oriented ResearchRecruitingIron Deficiency Anaemia in ChildbirthCanada
-
Assistance Publique - Hôpitaux de ParisAssociation Clinique Thérapeutique Infantile du val de Marne; Association Française... and other collaboratorsCompleted
-
American Regent, Inc.WithdrawnIron Deficiency, AnaemiaUnited States
Clinical Trials on IHAT
-
Nemysis LtdRDC Clinical Pty LtdRecruitingIron-deficiencyAustralia
-
RDC Clinical Pty LtdNot yet recruiting
-
Tufts UniversityBill and Melinda Gates FoundationRecruiting